Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Dril-Quip, Inc. (DRQ) - free report >>
Freshpet, Inc. (FRPT) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dril-Quip, Inc. (DRQ) - free report >>
Freshpet, Inc. (FRPT) - free report >>
Image: Bigstock
New Strong Sell Stocks for August 3rd
Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:
CAE Inc. (CAE - Free Report) is a world leader in providing simulation and modeling technologies, and integrated training services. The Zacks Consensus Estimate for its current year earnings has been revised 1.3% downward over the last 30 days.
Dril-Quip, Inc. (DRQ - Free Report) is one of the world's leading manufacturers of offshore drilling and production equipment. The Zacks Consensus Estimate for its current year earnings has been revised 31.6% downward over the last 30 days.
Freshpet, Inc. (FRPT - Free Report) is a pet food company. The Zacks Consensus Estimate for its current year earnings has been revised 20% downward over the last 30 days.
Orchid Island Capital, Inc. (ORC - Free Report) is a specialty finance company. The Zacks Consensus Estimate for its current year earnings has been revised 5.7% downward over the last 30 days.
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 2.5% downward over the last 30 days.
View the entire Zacks Rank #5 List.